Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
AT-101 by Abclon for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
AT-101 is under clinical development by Abclon and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData,...
AT-101 by Abclon for Mantle Cell Lymphoma: Likelihood of Approval
AT-101 is under clinical development by Abclon and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase...
AT-101 by Abclon for Follicular Lymphoma: Likelihood of Approval
AT-101 is under clinical development by Abclon and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II...
AT-101 by Abclon for Marginal Zone B-cell Lymphoma: Likelihood of Approval
AT-101 is under clinical development by Abclon and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...
AT-101 by Ascenta Therapeutics for Relapsed Multiple Myeloma: Likelihood of Approval
AT-101 is under clinical development by Ascenta Therapeutics and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData,...
AT-101 by Ascenta Therapeutics for Refractory Multiple Myeloma: Likelihood of Approval
AT-101 is under clinical development by Ascenta Therapeutics and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData,...
AT-101 by Abclon for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
AT-101 is under clinical development by Abclon and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...